Case Code : CLBS093
Publication date : 2009
Subject : Business Strategy
Industry : -
Length : 02 Pages
Price : Rs. 100
To download this case click on the button below, and select the case from the list of available cases:
Strategy, Trimeris, downsizing, research and development, fusion inhibitor technology, Fuzeon, TRI-1144, HealthCor, patent infringement, Novartis, drug delivery system, Pfizer, Merck, Roche
* This caselet is intended for use only in class discussions.
** More comprehensive case studies are priced at Rs.200 to Rs.700 (US $5 to US $16) per copy.
With sales of its only commercially available product failing to pick up significantly and the company being encircled by a number of problems, Trimeris announced its plans to downsize the company by scaling back its investments in research and development (R&D) and laying off workers.
Mattingly's announcement came close on the heels of Trimeris' announcement that it planned to launch a new version of its breakthrough drug Fuzeon, called TR-1144, in 2008...
Cases on Related Topics
1. Pricing Fuzeon: Cost of Innovation
2. Race-Specific Drug 'BiDil': Nitromed's Marketing Challenge
3. HSBC's Restructuring in India
4. Employee Downsizing - A Global Phenomenon